Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Tal Sigawi,
Ram Gelman,
Ofra Maimon
и другие.
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Июль 30, 2024
Introduction
The
main
obstacle
in
treating
cancer
patients
is
drug
resistance.
Lenvatinib
treatment
poses
challenges
due
to
loss
of
response
and
the
common
dose-limiting
adverse
events
(AEs).
Constrained-disorder-principle
(CDP)-based
second-generation
artificial
intelligence
(AI)
systems
introduce
variability
into
regimens
offer
a
potential
strategy
for
enhancing
efficacy.
This
proof-of-concept
clinical
trial
aimed
assess
impact
personalized
algorithm-controlled
therapeutic
regimen
on
lenvatinib
effectiveness
tolerability.
Methods
A
14-week
open-label,
non-randomized
was
conducted
with
five
receiving
lenvatinib—an
AI-assisted
application
tailored
each
patient,
which
physician
approved.
study
assessed
changes
tumor
through
FDG-PET-CT
markers
quality
life
via
EORTC
QLQ-THY34
questionnaire,
AEs,
laboratory
evaluations.
app
monitored
adherence.
Results
At
14
weeks
follow-up,
disease
control
rate
(including
following
outcomes:
complete
response,
partial
stable
disease)
80%.
scan-based
RECIST
v1.1
PERCIST
criteria
showed
40%
an
additional
patients.
One
patient
experienced
progressing
disease.
Of
participants
thyroid
cancer,
75%
reduction
thyroglobulin
levels,
60%
all
decrease
neutrophil-to-lymphocyte
ratio
during
treatment.
Improvement
median
social
support
score
among
utilizing
system
supports
ancillary
benefit
intervention.
No
grade
4
AEs
or
functional
deteriorations
were
recorded.
Summary
results
this
open-labeled
suggest
that
CDP-based
AI
system-generated
recommendations
may
improve
manageable
AEs.
Prospective
controlled
studies
are
needed
determine
efficacy
approach.
Язык: Английский
Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer
International Journal of Nanomedicine,
Год журнала:
2025,
Номер
Volume 20, С. 2623 - 2643
Опубликована: Март 1, 2025
In
recent
years,
nanobiotechnology,
widely
used
in
hepatoma,
holds
great
promise
for
improving
targeted
hepatocarcinoma
therapy.
On
account
of
the
unique
properties
low
toxicity,
good
tolerance,
biocompatibility,
and
biodegradability
new
nanomaterials,
a
drug
delivery
system
(TDDS)
has
been
constructed,
which
can
boost
therapeutic
effect
hepatoma-targeted
drugs,
reduce
minimize
off
target
reactions
by
enhancing
permeability
retention
(EPR)
active
targeting,
thus
existing
liver
cancer
therapy
strategies.
Different
nanoparticles
have
their
own
advantages
disadvantages.
They
be
loaded
with
multiple
drugs
on
same
nanoparticle
also
surface
modified
each
other
to
achieve
synergistic
anti-tumor
effects.
This
essay
provides
comprehensive
overview
current
status
hepatocarcinoma,
nanoparticles'
structure,
disadvantages
nanoparticle,
application
progress
cancer.
We
hope
provide
basis
future
clinical
hepatoma
using
nanotechnology.
Язык: Английский
NOVA2 regulates the properties of liver cancer stem cells and lenvatinib resistance in hepatocellular carcinoma via the Wnt pathway
Jing-Zhu Cao,
Chao-Qun Wang,
Zheng Shi
и другие.
Journal of Gastrointestinal Oncology,
Год журнала:
2024,
Номер
15(4), С. 1674 - 1685
Опубликована: Авг. 1, 2024
The
regulation
of
cancer
stem
cells
(CSCs)
is
influenced
by
RNA-binding
proteins
(RBPs).
present
study
sought
to
investigate
the
role
NOVA2
in
processes
self-renewal,
carcinogenesis,
and
lenvatinib
resistance
liver
CSCs.
Язык: Английский
Strategies to enhance the response of liver cancer to pharmacological treatments
AJP Cell Physiology,
Год журнала:
2024,
Номер
327(1), С. C11 - C33
Опубликована: Май 6, 2024
In
contrast
to
other
types
of
cancers,
there
is
no
available
efficient
pharmacological
treatment
improve
the
outcomes
patients
suffering
from
major
primary
liver
i.e.,
hepatocellular
carcinoma
and
cholangiocarcinoma.
This
dismal
situation
partly
due
existence
in
these
tumors
many
different
synergistic
mechanisms
resistance,
accounting
for
lack
response
patients,
not
only
classical
chemotherapy
but
also
more
modern
agents
based
on
inhibition
tyrosine
kinase
receptors
(TKIs)
stimulation
immune
against
tumor
using
checkpoint
inhibitors
(ICIs).
review
summarizes
efforts
develop
strategies
overcome
this
severe
limitation,
including
searching
novel
drugs
derived
synthetic,
semisynthetic,
or
natural
products
with
vectorial
properties
therapeutic
targets
increase
drug
uptake
reduce
export
cancer
cells.
Besides,
immunotherapy
a
promising
line
research
that
already
starting
be
implemented
clinical
practice.
Although
less
successful
than
foreseen
future
strategy
treating
cancers
considerable.
Similarly,
epigenetic
highly
promising.
Many
“epidrugs,”
able
act
“writer,”
“reader,”
“eraser”
players,
are
currently
being
evaluated
preclinical
studies.
Finally,
gene
therapy
broad
field
fight
chemoresistance,
impressive
advances
recently
achieved
manipulation.
sum,
although
present
still
dismal,
reason
hope
non-too-distant
future.
Язык: Английский
Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis
Heliyon,
Год журнала:
2024,
Номер
10(12), С. e32875 - e32875
Опубликована: Июнь 1, 2024
BackgroundRenal
Cell
Carcinoma
(RCC)
stands
as
a
formidable
challenge
within
the
field
of
oncology,
despite
considerable
research
endeavors.
The
advanced
stages
this
malignancy
present
barriers
to
effective
treatment
and
management.ObjectiveThis
review
aims
explore
potential
exosomes
in
addressing
diagnostic
therapeutic
challenges
associated
with
RCC.
Specifically,
it
investigates
role
biomarkers
vehicles
context
RCC
management.MethodsFor
article,
comprehensive
literature
search
was
conducted
using
databases
such
PubMed,
employing
relevant
keywords
identify
articles
pertinent
objectives
review.
Initially,
200
were
identified,
which
underwent
screening
remove
duplicates
assess
relevance
based
on
titles
abstracts,
followed
by
detailed
examination
full
texts.
From
selected
articles,
data
extracted
synthesized
address
review's
objectives.
conclusions
drawn
thorough
analysis
findings.
quality
ensured
through
independent
resolution
discrepancies
among
multiple
reviewers.ResultsExosomes
demonstrate
tools
for
early
detection,
prognosis,
monitoring
Their
ability
deliver
various
agents,
small
interfering
RNAs,
lncRNAs,
chemotherapeutic
drugs,
immune-stimulating
allows
personalized
approach
management.
By
leveraging
exosome-based
technologies,
precision
efficacy
strategies
can
be
significantly
enhanced.ConclusionDespite
promising
advancements
enabled
management
RCC,
further
is
necessary
refine
technologies
validate
their
efficacy,
safety,
long-term
benefits
rigorous
clinical
trials.
Embracing
integral
components
diagnosis
represents
significant
step
towards
improving
patient
outcomes
persistent
posed
oncology.
Язык: Английский
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma
European Urology Focus,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 24, 2024
Anaplastic
thyroid
cancer
(ATC)
is
the
most
lethal
tumor
arising
from
follicular
epithelium.
Lenvatinib
an
off-label
use
option
for
ATC
patients
in
many
countries
but
approved
prescription
Japan.
However,
lenvatinib
resistance
a
substantial
clinical
challenge.
Clinical
samples
including
lenvatinib-resistant
tumors
are
used
to
build
patient-derived
cells
and
xenografts.
High-throughput
drug
screening
synergy
analyses
performed
identify
effective
combination
partner
lenvatinib.
Cellular
functions
detected
by
cell
senescence,
apoptosis,
cycle,
viability
colony
formation
assays.
CDK2
inhibition
showed
significant
synthetic
lethality
with
via
inhibiting
G1/S
transition
inducing
senescence
ATC.
High
expression
of
associated
poor
outcomes
patients.
increased
protein
cells.
Mechanistically,
inhibited
degradation
reducing
CDK2's
interaction
RACK1-FBW7
complex,
which
involved
ubiquitination
subsequent
proteasomal
CDK2.
Combination
inhibitors
trials
(Dinaciclib
or
PF-07104091)
markedly
suppressed
growth
xenograft
patient.
The
findings
support
therapy
strategy
inhibitor
high
expression.
Язык: Английский